Mucor and Malignancy: A Double-Hit Case of Intestinal Ischemia : ACG Case Reports Journal

Secondary Logo

Journal Logo

CASE REPORT: COLON

Mucor and Malignancy: A Double-Hit Case of Intestinal Ischemia

Berger, Benjamin T. MD1; Townsend, Matthew J. MD, MSc, MPP1; Arbogast, Mitchell K. MD2; Van Kirk, Jenny MD1

Author Information
ACG Case Reports Journal 9(12):p e00907, December 2022. | DOI: 10.14309/crj.0000000000000907
  • Open

Abstract

INTRODUCTION

Mucormycosis describes invasive infections by molds in the order Mucorales, typically Rhizopus and Mucor species.1 These molds are ubiquitous in the environment, especially in soil and decaying organic matter.2 They produce spores to which humans are exposed through inhalation, ingestion, or inoculation. Risk factors for Mucorales infections include solid organ or bone marrow transplantation, hematologic malignancy, neutropenia, corticosteroid use, trauma, and diabetes mellitus, particularly with diabetic ketoacidosis (DKA).3,4 Recently, coronavirus disease 2019 (COVID-19) has been identified as a risk factor of mucormycosis, possibly because of immunomodulatory effects of the virus and steroids used in its management.5,6 Although mucormycosis most commonly presents with rhino-orbital-cerebral involvement, primary gastrointestinal mucor represents approximately 7%–8% of mucormycosis cases.1,7 Treatment for any pattern includes surgical source control and polyene antifungal therapy. Mortality ranges from 25% (isolated sinus disease) to >90% (disseminated disease).1 We describe a case of angioinvasive gastrointestinal mucormycosis presenting with colonic ischemia in a patient with recent DKA and undiagnosed colon adenocarcinoma.

CASE REPORT

A 77-year-old woman presented with 2 weeks of epigastric pain, nausea, and poor oral intake. Medical history was notable for long-standing type 2 diabetes mellitus poorly controlled on metformin (A1c 10.7%). She had a metabolic acidosis (pH 7.02, bicarbonate 6 mEq/L), hyperglycemia (862 mg/dL), and elevated beta-hydroxybutyrate consistent with DKA. Aspartate and alanine transaminases, alkaline phosphatase, and total bilirubin were elevated at 148, 370, 658 U/L, and 7.7 mg/dL, respectively. The patient underwent abdominal ultrasound and computed tomography (CT), which demonstrated duodenal thickening concerning for duodenitis but did not reveal an etiology of her cholestasis. Her DKA resolved with intravenous insulin and fluids. She was transferred to our medical center for advanced gastroenterological evaluation.

On transfer, physical examination demonstrated upper abdominal tenderness without signs of peritonitis. Laboratory studies showed leukocytosis and persistent liver enzyme elevations in a cholestatic pattern. The patient was treated with piperacillin-tazobactam and vancomycin for possible cholangitis. Magnetic resonance cholangiopancreatography showed luminal irregularities and dilation of the left and right intrahepatic bile ducts with focal narrowing of the common hepatic duct and wall thickening of the common bile duct. Subsequent endoscopic retrograde cholangiopancreatography showed malignant-appearing strictures of the common hepatic and common bile ducts. Brushings were obtained, and the common bile duct was stented. Pathology of bile duct brushings revealed an abnormal ductal epithelium suspicious for adenocarcinoma. On postprocedure day 2, the patient had multiple maroon bowel movements. Mesenteric CT angiography showed new colonic wall thickening but did not identify active bleeding or thrombosis. The patient developed worsening abdominal pain and leukocytosis, and interval abdominal CT displayed worsening ascending colonic inflammation (Figure 1).

F1
Figure 1.:
Abdominal and pelvic computed tomography with intravenous and oral contrast showing segmental wall thickening of the ascending colon (arrow) consistent with colitis. The biliary stent is also visualized (arrowhead).

The patient underwent diagnostic laparoscopy, which revealed a necrotic ascending and transverse colon with perforation. Right hemicolectomy and end ileostomy were performed. Echocardiogram demonstrated normal cardiac function. The colitis was presumed to be ischemic in etiology, although no preceding hypotension had been observed, and there was no evidence of thromboembolism. On postprocedure day 12, histopathology of the resected colon revealed angioinvasive mucormycosis (Figure 2). In addition, an occult adenocarcinoma was identified with extensive lymphovascular invasion and lymph node metastases. Fungal elements and neoplastic cells were seen in close association (Figure 2). Her presenting cholestasis was consistent with malignant biliary obstruction from this primary colon adenocarcinoma.

F2
Figure 2.:
Representative histologic photomicrographs. (A) Broad nonseptate fungal hyphae with a 90° angle branching involving the muscular wall of the colon, morphologically consistent with mucormycosis (H&E ×40). (B) Intravascular colonic adenocarcinoma involving large mesenteric veins (H&E ×4). (C) Angioinvasive fungus involving a mesenteric artery with associated thrombus formation and an adjacent focus of adenocarcinoma (H&E ×10). (D) High-power view of invasive adenocarcinoma colliding with fungal hyphae (H&E ×40). H&E, hematoxylin and eosin.

Liposomal amphotericin B was initiated for mucormycosis. Evaluation of other sites of involvement was pursued with head magnetic resonance imaging, which showed no evidence of rhino-orbital-cerebral disease, and CT chest, which showed nonspecific tree-in-bud nodularity of the upper lobes. The patient developed progressive renal dysfunction on amphotericin and was transitioned to isavuconazole. Her course was complicated by worsening malnutrition and anasarca. She decided to pursue hospice care and unfortunately died 1 month after discharge.

DISCUSSION

Gastrointestinal mucormycosis carries high morbidity and mortality. While incidence varies globally, country-level data suggest a rising incidence of mucormycosis—for example, from 0.7 to 1.2 per million in France from 1997 to 2006—which may reflect increased detection and/or risk factors including diabetes mellitus (450–720 cases per million globally in the same period).8-10 The stomach is the most common site of gastrointestinal involvement, followed by the colon and ileum.1,7 Angioinvasion is a hallmark pathogenic feature that causes thrombosis and ischemia. Accordingly, gastrointestinal mucor can present with abdominal pain, nausea, vomiting, and gastrointestinal bleeding; bowel perforation is common in advanced disease. Bowel wall thickening or pneumatosis may be observed on imaging.11,12 Because symptoms and imaging are nonspecific and serologic testing is limited, diagnosis remains challenging and relies on histopathology.13 In one series, only 25% of gastrointestinal mucormycosis cases were identified antemortem.1 Early identification of risk factors may facilitate timely diagnosis.

Our patient's best established risk factor was poorly controlled diabetes with recent DKA. She also presented with malnutrition likely secondary to her later-diagnosed malignancy, which has been associated especially with the development of gastrointestinal mucormycosis.1 Although nosocomial outbreaks from colonized materials have been described, endoscopic equipment contamination is unlikely in our patient because her ischemic symptoms began within 48 hours after endoscopic retrograde cholangiopancreatography. Colon adenocarcinoma likely acted synergistically in the development of invasive mucormycosis. The extensive intravascular tumor observed on pathology contributed to ischemia, creating a local hypoxic and acidic tissue microenvironment in which Mucorales thrives.14 Iron content is increased in colon tumor tissue, and Mucorales are well known for their iron avidity.15,16

Treatment of mucormycosis relies on source control and antifungal therapy.17 Surgical intervention and early initiation of amphotericin B are associated with improved survival.18,19Mucorales is most reliably sensitive to amphotericin B, but isavuconazole and posaconazole are used as step-down or salvage therapy. Antifungal therapy is complicated by susceptibility variations between and within Mucorales species, drug toxicities, poor correlation between in vitro and in vivo activity, and tissue ischemia, which impedes delivery to the infection site(s).3,19 Gastrointestinal mucormycosis should trigger evaluation for rhino-orbito-cerebral, pulmonary, cutaneous, or disseminated mucor; in our patient, the duodenitis and pulmonary tree-in-bud opacities observed on CT imaging may have represented multiorgan disease. This case should encourage clinicians to remain vigilant for mucormycosis, an increasingly prevalent infection with diverse clinical manifestations and high mortality that can be improved with prompt recognition and treatment.

DISCLOSURES

Author contributions: BT Berger and MJ Townsend wrote the manuscript and reviewed the literature. MK Arbogast provided histopathology images. MK Arbogast and J. Van Kirk revised the manuscript for intellectual content. J. Van Kirk is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

REFERENCES

1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23–34.
2. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8(9):1163–75.
3. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S16–22.
4. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
5. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis–Arkansas, July-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(50):1750–1.
6. Danion F, Letscher-Bru V, Guitard J, et al. COVID-19 associated mucormycosis in France: A rare but deadly complication. Open Forum Infect Dis. 2021;9(2):ofab566.
7. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.
8. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26.
9. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009;15(9):1395–401.
10. Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Sci Rep. 2020;10:14790.
11. Ghuman SS, Sindhu P, Buxi TBS, et al. CT appearance of gastrointestinal tract mucormycosis. Abdom Radiol (NY). 2021;46(5):1837–45.
12. Kruger AJ, Modi RM, Yearsley M, Ugbarugba EE. Development of mucormycosis colitis during prolonged hospitalization. ACG Case Rep J. 2017;4:e56.
13. Millon L, Scherer E, Rocchi S, Bellanger AP. Molecular strategies to diagnose mucormycosis. J Fungi (Basel). 2019;5(1):E24.
14. Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis–The bitter and the sweet. PLoS Pathog. 2017;13(8):e1006408.
15. Xue X, Shah YM. Intestinal iron homeostasis and colon tumorigenesis. Nutrients. 2013;5(7):2333–51.
16. Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol Infect. 2009;15(Suppl 5):26–32.
17. Arif S, Perfect JR. Emergence of the molds other than aspergillus in immunocompromised patients. Clin Chest Med. 2017;38(3):555–73.
18. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.
19. Lamoth F, Kontoyiannis DP. Therapeutic challenges of non-aspergillus invasive mold infections in immunosuppressed patients. Antimicrob Agents Chemother. 2019;63(11):e01244-19.
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.